Mercado global de tratamento da síndrome de Reye – Tendências do setor e previsão para 2028

Análise de mercado e insights: mercado global de tratamento da síndrome de Reye

Espera-se que o mercado de tratamento da síndrome de Reye ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer a um CAGR de 5,80% no período de previsão da pesquisa acima referido. Aumento da população de crianças em todo o mundo e casos crescentes de infeções por influenza entre crianças.

O avanço nas ferramentas de diagnóstico para diagnosticar com precisão os sintomas da doença e o desenvolvimento da biotecnologia e do setor farmacêutico também impulsionam o crescimento do mercado. Além disso, o aumento da parceria e colaboração entre os participantes do mercado e o aumento do rendimento per capita funcionam como uma oportunidade para o crescimento do mercado. Mas a falta de sensibilização para a doença, as opções de tratamento limitadas e as regulamentações rigorosas podem dificultar o mercado global de tratamento da síndrome de Reye .

A síndrome de Reye é caracterizada como uma das doenças raras que causa danos cerebrais e hepáticos. Pode afetar em qualquer fase da vida as crianças. As crianças que passaram recentemente por qualquer infeção viral são mais propensas à síndrome de Reye; além disso, a ingestão elevada de aspirina também aumenta as probabilidades da síndrome de Reye. Os agentes patogénicos virais mais comummente relatados responsáveis ​​por causar a síndrome de Reye incluem a gripe A e B juntamente com a varicela. De acordo com o CDC, a síndrome de Reye é definida como encefalopatia aguda não inflamatória marcada por alteração da consciência, registo de líquido cefalorraquidiano menor ou igual a 8 leucócitos/mm3 com inflamação meníngea. As crianças que sofrem da síndrome de Reye devem ser submetidas a um procedimento cirúrgico que inclui a colocação de um acesso venoso central, intubação das vias aéreas e cateter de Foley . Além disso, são também realizadas biópsias hepáticas e monitorização da pressão intracraniana para manter a saúde das crianças que sofrem da síndrome de Reye. O tratamento agressivo sugerido para a síndrome de Reye inclui a administração de fluidos intravenosos, diuréticos, corticosteróides para reduzir os sintomas inflamatórios, medicamentos para prevenir hemorragias, entre outros.

The increasing case of viral infections among children is one of the major causes of Reye syndrome. As per the NCBI publication of 2020, this has been estimated that seasonal virus influenza is one of the major causes of respiratory infection in children. This has been concluded that in 2018, globally about 109. 5 million children under the age of 5 years suffered from acute lower respiratory infection caused by influenza virus. As the prevalence of viral infections is increasing at a rapid rate is expected to boost up the number of Reye syndrome patients and hence expected to provide market with the lucrative growth.

This Reye syndrome treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Reye Syndrome Treatment Market Scope and Market Size

Reye syndrome treatment market is segmented on the basis of treatment, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of treatment, the Reye syndrome treatment market is segmented into intravenous fluids, corticosteroids, diuretics, antifibrinolytics, surgery, others. Intravenous segment is further sub-segmented into dextrose 5%, 0.9% normal saline, lactated ringers, others. Corticosteroids segment is further sub-segmented into dexamethasone and others. Antifibrinolytics is sub-segmented into tranexamic acid and others.
• On the basis of end-users, the Reye syndrome treatment market is segmented into clinics, hospitals, research laboratories, ambulatory surgical centre, others.
• On the basis of distribution channel, the Reye syndrome treatment market has also been segmented into retail pharmacy, hospital pharmacy, others. 

Reye Syndrome Treatment Market Country Level Analysis

Reye syndrome treatment market is analysed and market size information is provided by country, treatment, end-users and distribution channel as referenced above.

The countries covered in the Reye syndrome treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the presence of a well-developed healthcare sector and rising healthcare expenditures. Moreover increasing children population susceptible to influenza infection is another factor driving the market growth. Europe accounts the second largest market share due to availability of funds for research activities related to rare diseases and presence of huge patient’s population. Asia-Pacific is expected to account for the largest market share over coming years for the Reye syndrome treatment market due to rising government support for children health and increasing investment for development of pharmaceutical and biotechnology industries.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Reye syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Reye Syndrome Treatment Market Share Analysis

O cenário competitivo do mercado de tratamento da síndrome de Reye fornece detalhes por concorrente, os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, locais e instalações de produção, pontos fortes e fracos da empresa, lançamento do produto, pipelines de ensaios clínicos, aprovações de produtos, patentes, largura e amplitude do produto, domínio da aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de tratamento da síndrome de Reye.

Os principais players abrangidos no mercado de tratamento da síndrome de Reye são a Pfizer Inc., Novartis AG, Merck KGaA, Sanofi SAIS, Baxter, Zydus Cadila, Par Pharmaceutical, Aspen Australia, Hikma, Cipla Inc., XSPIRE PHARMA, ACHÉ LABORATÓRIOS FARMACÊUTICOS SA , Lupin Pharmaceuticals, Inc., Salius Pharma Private Limited, Soxa Formulations & Research (Pvt.) Ltd, Ami Lifesciences, Hangzhou Longshine Bio-Tech Co., LTD., Schwitz Biotech, B. Braun Medical Inc., Fresenius Kabi India Unip . Ltd., Beximco Pharmaceuticals Ltd., entre outros players nacionais e globais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

SKU-60217